Sivik Global Healthcare LLC raised its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,000 shares of the pharmaceutical company’s stock after purchasing an additional 5,000 shares during the period. Vertex Pharmaceuticals makes up approximately 2.6% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 9th biggest position. Sivik Global Healthcare LLC’s holdings in Vertex Pharmaceuticals were worth $7,088,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Guardian Life Insurance Co. of America raised its position in Vertex Pharmaceuticals by 0.6% during the first quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock valued at $105,000 after purchasing an additional 6 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Vertex Pharmaceuticals by 15.4% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock valued at $127,000 after purchasing an additional 132 shares in the last quarter. FNY Partners Fund LP raised its position in Vertex Pharmaceuticals by 900.0% during the second quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock valued at $128,000 after purchasing an additional 900 shares in the last quarter. Dupont Capital Management Corp acquired a new position in Vertex Pharmaceuticals during the second quarter valued at approximately $186,000. Finally, State of Alaska Department of Revenue acquired a new position in Vertex Pharmaceuticals during the second quarter valued at approximately $197,000. Institutional investors and hedge funds own 92.88% of the company’s stock.
VRTX has been the subject of several research analyst reports. Vetr upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and set a $119.50 price objective for the company in a research report on Tuesday, May 30th. Oppenheimer Holdings, Inc. upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $150.00 price objective for the company in a research report on Friday, June 2nd. CIBC upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Friday, June 2nd. Jefferies Group LLC restated a “buy” rating and set a $126.00 price objective on shares of Vertex Pharmaceuticals in a research report on Friday, June 9th. Finally, Leerink Swann restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, June 22nd. Six research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $163.35.
In related news, CMO Jeffrey Chodakewitz sold 3,438 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $127.80, for a total transaction of $439,376.40. Following the sale, the chief marketing officer now owns 125,949 shares of the company’s stock, valued at $16,096,282.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey M. Leiden sold 216,624 shares of the business’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $160.96, for a total transaction of $34,867,799.04. Following the sale, the chief executive officer now directly owns 400,266 shares in the company, valued at approximately $64,426,815.36. The disclosure for this sale can be found here. Insiders have sold 526,092 shares of company stock worth $84,101,702 in the last three months. 1.80% of the stock is currently owned by insiders.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded up 0.15% during trading on Friday, hitting $153.61. 3,112,907 shares of the stock were exchanged. The stock has a 50 day moving average of $154.58 and a 200-day moving average of $127.13. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $167.86. The stock has a market cap of $38.73 billion, a P/E ratio of 147.56 and a beta of 1.75.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The business had revenue of $544.10 million for the quarter, compared to analyst estimates of $489.95 million. During the same quarter in the previous year, the firm posted $0.24 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 26.1% on a year-over-year basis. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post $1.60 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Sivik Global Healthcare LLC Purchases 5,000 Shares of Vertex Pharmaceuticals Incorporated (VRTX)” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://ledgergazette.com/2017/09/17/sivik-global-healthcare-llc-purchases-5000-shares-of-vertex-pharmaceuticals-incorporated-vrtx.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.